Patients with specific AKI stages or non-responders may benefit from the combined effects of albumin and terlipressin, as supported by various trials [39], including those on acute-on-chronic liver failure and paracentesis-associated AKI [40]. This evidence concerns the gene ALB and acute kidney injury.